Analysts See $-0.19 EPS for Ablynx NV (ABLYF)

May 16, 2018 - By Larry Park


Analysts expect Ablynx NV (OTCMKTS:ABLYF) to report $-0.19 EPS on May, 24. It closed at $53.3 lastly. It is down 0.00% since May 16, 2017 and is . It has underperformed by 11.55% the S&P500.

Ablynx NV, a biopharmaceutical company, develops Nanobodies that is a proprietary therapeutic protein based on single-domain antibody fragments for the treatment of various diseases. The company has market cap of $4.05 billion. The firm develops products in various therapeutic areas, such as inflammation, hematology, immuno-oncology, oncology, and respiratory diseases. It currently has negative earnings. The Company’s clinical programs include caplacizumab, an anti-vWF Nanobody that is in Phase III clinical trial to treat acquired thrombotic thrombocytopenic purpura; ALX-0171, an anti-RSV Nanobody, which is in Phase IIb clinical trial for the treatment of respiratory syncytial virus infection; and Vobarilizumab, an anti-IL-6R Nanobody that is in Phase IIb clinical trial for the treatment of rheumatoid arthritis, as well as in Phase II clinical trial to treat systemic lupus erythematosus.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.